SARS-CoV 2 Clinical Trial
Official title:
Exploring Brain Damages After COVID-19 Infection
Although direct evidence is currently lacking, the high identity between SARS-CoV-1 and SARS-CoV-2 suggests, that the latter viral strain could also infect the Central Nervous System (CNS). Indeed, some cases of SARS-COV2 encephalitis begin to be described and CNS damages are increasingly highlighted in the literature, but still not objectified by imaging and do not allow to explain the entire clinical patterns. We hypothesise that these CNS damages are not always objectified by Magnetic Resonance Imaging (MRI) but could be indirectly observed by a physiological dysfunction of neural conduction in the brainstem. We will explore brainstem disruption through an electrophysiological approach.
Clinical and preclinical data from studies with other coronaviruses suggest an evident neurotropism, which may result in more complex clinical scenarios. Can the SARS-CoV-2 enter the Central Nervous System (CNS) and infect neural cells ? And if yes, how the CNS damage contributes to pathophysiology of the COVID-19, to its signs, symptoms and progression as well as to its sequelae. It has been demonstrated that coronaviruses such as SARS-CoV and MERS-CoV do not limit their presence to the respiratory tract and frequently invade the CNS. The intranasal administration of SARS-CoV-1 or MERS-COV resulted in the rapid invasion of viral particles into the brain of mice, possibly through the olfactory bulb via trans-synaptic route. The brainstem, which hosts the respiratory neuronal circuit in the medulla, was severely infected with both types of viruses, which may contribute to degradation and failure of respiratory centres. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04410510 -
P2Et Extract in the Symptomatic Treatment of Subjects With COVID-19
|
Phase 2/Phase 3 | |
| Withdrawn |
NCT04456426 -
Characteristics of Patients With COVID-19 in Meta State, Colombia
|
||
| Suspended |
NCT04385771 -
Cytokine Adsorption in Patients With Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation
|
N/A | |
| Withdrawn |
NCT04386447 -
Phase II RCT to Assess Efficacy of Intravenous Administration of Oxytocin in Patients Affected by COVID-19
|
Phase 2 | |
| Terminated |
NCT04435457 -
Cardiovascular Implications of COVID-19
|
||
| Completed |
NCT04357834 -
WAVE. Wearable-based COVID-19 Markers for Prediction of Clinical Trajectories
|
||
| Completed |
NCT04405934 -
COG-UK Project Hospital-Onset COVID-19 Infections Study
|
N/A | |
| Completed |
NCT04615936 -
Nasal Photodisinfection COVID-19 Proof of Concept Study
|
N/A | |
| Completed |
NCT04369794 -
COVID-19: BCG As Therapeutic Vaccine, Transmission Limitation, and Immunoglobulin Enhancement
|
Phase 4 | |
| Terminated |
NCT04401410 -
Anti-SARS Cov-2 T Cell Infusions for COVID 19
|
Phase 1 | |
| Completed |
NCT04542850 -
Pilot Study to Evaluate the Safety, Tolerability, and Efficacy of 5-ALA-Phosphate + SFC in Subjects With COVID-19
|
N/A | |
| Completed |
NCT04382040 -
A Phase II, Controlled Clinical Study Designed to Evaluate the Effect of ArtemiC in Patients Diagnosed With COVID-19
|
Phase 2 | |
| Completed |
NCT04366908 -
Prevention and Treatment With Calcifediol of COVID-19 Induced Acute Respiratory Syndrome
|
Phase 2 | |
| Completed |
NCT04378582 -
Characteristics and Outcomes of Patients With COVID-19 Admitted to the ICU
|
||
| Completed |
NCT04383587 -
Seroprevalence of SARS CoV 2 Antibodies in Previously Undiagnosed Healthcare Workers
|
N/A | |
| Recruiting |
NCT04402814 -
IgG/IgM Antibody Test in Patients Who Have Tested Negative or Positive for COVID-19 With the Standard Method of COVID19 Testing.
|
||
| Completed |
NCT04374565 -
Convalescent Plasma for Treatment of COVID-19 Patients With Pneumonia
|
Phase 2 | |
| Completed |
NCT04395924 -
Maternal-foetal Transmission of SARS-Cov-2
|
||
| Completed |
NCT04425889 -
COVID-19 Antibodies Among Healthcare Workers
|
||
| Completed |
NCT04413071 -
Cardiac COVID-19 Health Care Workers
|